Technical Analysis for ATOS - Atossa Genetics Inc.

Grade Last Price % Change Price Change
grade F 2.01 0.00% 0.00
ATOS closed unchanged on Wednesday, September 18, 2019, on 36 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Earnings due: Sep 27

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical ATOS trend table...

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
NR7 Range Contraction 0.00%
Inside Day Range Contraction 0.00%
20 DMA Resistance Bearish 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
20 DMA Resistance Bearish 0.00%
1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
Inside Day Range Contraction 0.00%

Older signals for ATOS ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Atossa Genetics, Inc. operates as a healthcare company that focuses on the development and marketing of cellular and molecular diagnostic risk assessment products for breast cancer in the United States. Its diagnostic tests include the ForeCYTE Breast Health Test, which provides personalized information about the 10-year and lifetime risk of breast cancer for women between ages 18 and 65; and the ArgusCYTE Breast Health Test that offers information to help inform breast cancer treatment options and to help monitor potential recurrence. The company also intends to offers FullCYTE Breast Health Test, which is in development to assess the individual breast ducts for pre-cancerous changes in women; and NextCYTE Breast Cancer Test that is in the prevalidation phase to profile breast cancer specimens for prediction of treatment outcomes and distant recurrence in women newly diagnosed with breast cancer. Atossa Genetics, Inc. was founded in 2009 and is headquartered in Seattle, Washington.
Medicine Health Cancer Healthcare Breast Cancer Diagnostic Tests Breast Implant Breast Surgery
Is ATOS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 3 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 7.39
52 Week Low 0.8
Average Volume 141,250
200-Day Moving Average 2.1419
50-Day Moving Average 2.0958
20-Day Moving Average 2.0373
10-Day Moving Average 2.0525
Average True Range 0.1161
ADX 27.94
+DI 20.1872
-DI 15.619
Chandelier Exit (Long, 3 ATRs ) 1.9017
Chandelier Exit (Short, 3 ATRs ) 2.2783
Upper Bollinger Band 2.133
Lower Bollinger Band 1.9416
Percent B (%b) 0.36
BandWidth 9.394787
MACD Line -0.0243
MACD Signal Line -0.0257
MACD Histogram 0.0014
Fundamentals Value
Market Cap 23.52 Million
Num Shares 11.7 Million
EPS -1.95
Price-to-Earnings (P/E) Ratio -1.03
Price-to-Sales 0.00
Price-to-Book 2.23
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.10
Resistance 3 (R3) 2.10 2.08 2.09
Resistance 2 (R2) 2.08 2.05 2.08 2.08
Resistance 1 (R1) 2.04 2.04 2.03 2.04 2.07
Pivot Point 2.02 2.02 2.01 2.02 2.02
Support 1 (S1) 1.98 1.99 1.97 1.98 1.95
Support 2 (S2) 1.96 1.98 1.96 1.94
Support 3 (S3) 1.92 1.96 1.94
Support 4 (S4) 1.92